linjc16/ctgov huggingface dataset:
A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
To demonstrate that clinical surrogates of SICU patients who view a video decision aid in addition to receiving written and verbal information about procedures and life sustaining therapy in the SICU make more informed decisions than patients and clinical surrogates who receive written and verbal information alone.

Detailed Description
-----------------
Specific Aim 1: To demonstrate that clinical surrogates of SICU patients who view a video decision aid in addition to receiving written and verbal information about procedures and life sustaining therapy in the SICU make more informed decisions than patients and clinical surrogates who receive written and verbal information alone. Hypothesis 1: Adding a video decision aid to the current informed consent process, for procedures and life sustaining treatments in the SICU, will better inform clinical surrogates of incapacitated patients admitted to the SICU regarding decision making when providing consent for medical treatment.

Official Title
-----------------
A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit

Conditions
-----------------
Surgery, Trauma

Intervention / Treatment
-----------------
* Behavioral: video decision aid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical surrogates of the following patients will be eligible to participate in this opinion survey: All patients admitted to the SICU and not expected to die within 48 hours. Patient has been admitted to the acute care surgical service, The patient is over the age of 50 and does not have decision making capacity. Subjects must be over the age of 21 and English speaking to participate in the opinion survey. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control group<br>usual care | |
| Experimental: Video Arm<br> | Behavioral: video decision aid<br>* video decision aid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge of risks and benefits of procedures | knowledge of risks and benefits of procedures | 5 minutes after survey |
MicroRNA Expression in Human Blood Serum and Vitreous Body

Study Overview
=================
Brief Summary
-----------------
MicroRNAs are important regulators of many cellular functions but their expression profile in human vitreous is still unclear. Aim of this study is to investigate microRNA expression profile by PCR in human vitreous of macula hole patients which is suggested to be similar to that of healthy patients.

Official Title
-----------------
MicroRNA Expression in Human Blood Serum and Vitreous Body

Conditions
-----------------
MicroRNA Expression Profile in Human Vitreous

Intervention / Treatment
-----------------
* Procedure: human vitreous and blood serum sampling, PCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female macula hole patients without previous ocular or systemic disease.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| human vitreous, human blood serum, PCR<br>Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease | Procedure: human vitreous and blood serum sampling, PCR<br>* 1ml of human vitreous and 3ml of human blood serum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MicroRNA expression profile in human vitreous investigated by PCR |  | 1month |
Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods

Study Overview
=================
Brief Summary
-----------------
The purpose of this echocardiographic study is to restudy the longitudinal changes in cardiac size and function during and after pregnancy in healthy women using relatively new parameters of systolic and diastolic function as well as classical measures of left ventricle (LV) function using contemporary echocardiographic machines. We, the researchers at Hillel Yaffe Medical Center, will assess diastolic function and its possible relation to shortness of breath.

Detailed Description
-----------------
A comprehensive echocardiographic study of the heart will be conducted in the first, second and third trimesters of pregnancy and 3 months postpartum. Determination of left ventricular dimensions, transvalvular Doppler flow, ejection fraction, stroke volume, cardiac output, pulmonary vein flow, tissue Doppler, flow propagation, global and segmental strain parameters, timing of peak strain and various parameters of diastolic function will be obtained. From these data normal values for various stages of pregnancy will be determined as well as range for changes expected during longitudinal follow-up will be determined.

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women First trimester of a normal pregnancy Normal baseline echocardiogram Exclusion Criteria: Pregnancy with more than one fetus. Any hemodynamically significant cardiac condition Any known systemic disease Poor quality echocardiogram
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myocardial strain, Myocardial function, Pregnancy, Postpartum, Echocardiography, Myocardial adaptation to pregnancy, Systolic function, Diastolic function
Influences of Types of Skull Surgery on Temporomandibular Joint Performance

Study Overview
=================
Brief Summary
-----------------
There are two purposes on this study: - to investigate the effect of craniectomy and craniotomy on temporomandibular joint TMJ) movement, function and quality of life (QoL)

Official Title
-----------------
Influences of Types of Skull Surgery on Temporomandibular Joint Performance

Conditions
-----------------
Craniotomy, Craniectomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 20 years old post-craniotomy or post-craniectomy able to follow order Exclusion Criteria: severe orofacial injury severe teeth loss significant changes of occlusion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Surgery<br>Craniotomy or Craniectomy | |
| Control<br>age, gender and teeth condition matched | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Jaw movement |  | within 1 year after surgery | 
| Jaw Functional Limitation Scale |  | within 1 year after surgery | 
| Bite force |  | within 1 year after surgery | 
| WHOQOL-BREF Taiwanese Version |  | within 1 year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
craniotomy, craniectomy, temporalis, TMJ, mastication, QoL
Intra-abdominal Pressures During the Spontaneous Breathing Trial

Study Overview
=================
Brief Summary
-----------------
Increased intra-abdominal pressure (IAP) affects pulmonary dynamics. However, little is studied whether pulmonary dynamics affects IAP. We hypothesize that the change of IAP can also reflect the change of pulmonary dynamics. In this study, we choose patients who received spontaneous breathing trial to answer the hypothesis.

Detailed Description
-----------------
During the weaning process, we tapered down the respiratory support from mechanical ventilation and recruited respiratory muscles to work. Previous study showed that transdiaphragmatic pressure was increasing while pressure support was reducing. However, the transdiaphragmatic pressure required invasive procedure to measure and not used frequently in weaning. IAP reflects the pleural pressure. If the PEEP is not changed, change of IAP is largely due to change of transpulmonary pressure. Study Aim: To evaluate the patterns of change of IAP during SBT To predict success of SBT by the change of IAP To predict weaning outcome by the change of IAP

Official Title
-----------------
Measuring the Change of Intra-abdominal Pressures of the Intensive Care Unit Patients During the Spontaneous Breathing Trial

Conditions
-----------------
Respiratory Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with endotracheal intubation in the intensive care unit The clinical condition is considered to prepare for weaning assessment Exclusion Criteria: tracheostomy severe heart failure, heart disease or arrhythmia upper airway obstruction related respiratory failure poor cooperation due to agitation no foley catheter in place or had been removed baseline IAP above 20 mmHg

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the patterns of change of IAP during SBT | 30min, 60min, 120min during a 2-hr SBT | 30min, 60min, 120min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To predict success of SBT by the change of IAP | To predict success of 2-hour IAP the change of IAP between 0 min and 30 min, and tha change of IAP beween 0 min and 120 min | 0 min, 30 min, 120 min | 
| To predict weaning success by the change of IAP | To predict weaning success by the change of IAP between 0 min and 30 min, and tha change of IAP beween 0 min and 120 min | 0 min, 30 min, 120 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intra-abdominal pressure, spontaneous breathing trail, weaning
Sensitivity Diagnosing Traumatic Knee Injuries With and Without Injection of Blue Dye Into the Knee Joint

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if adding blue dye improves the saline load test, which is a way to detect a traumatic intraarticular knee injury by injecting normal saline into the knee and looking for outflow through the wound.

Official Title
-----------------
Sensitivity of the Saline Load Test With and Without Methylene Blue Dye in the Diagnosis of Traumatic Knee Arthrotomies

Conditions
-----------------
Traumatic Knee Arthrotomy

Intervention / Treatment
-----------------
* Procedure: Saline Load Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals with diagnosis warranting elective knee arthroscopy Exclusion Criteria: Pregnant women Decreased knee range of motion (flex < 125, ext <0) Active infection of knee joint history of or current intraarticular knee malignancy history of open traumatic injury of the knee

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Normal Saline<br>Normal Saline injected intraarticularly into the knee joint | Procedure: Saline Load Test<br>* Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.<br>|
| Experimental: Dilute Methylene Blue Dye<br>1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee | Procedure: Saline Load Test<br>* Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume (mm) injected at time of outflow |  | 1 month |
Microcirculatory Changes During Magnesium Sulphate Infusion in Sepsis

Study Overview
=================
Brief Summary
-----------------
During infections (sepsis) bloodflow in small vessels (microcirculation) becomes disturbed. Restoration of bloodpressure and cardiac performance may not be sufficient to correct these alterations. Magnesium is a potent vasodilator which may be used to open up the small vessels, in order to reduce organ failure.

Detailed Description
-----------------
In a single-center open label study we evaluated the effects of magnesium sulphate (MgS) infusion on the sublingual microcirculation perfusion in fluid resuscitated patients with severe sepsis and septic shock within the first 48 hours after ICU admission. Directly prior to and after 1 hour of magnesium sulphate (MgS) infusion (2 gram) systemic hemodynamic variables, sublingual SDF images and standard laboratory tests, were obtained.

Official Title
-----------------
Microcirculatory Changes During Open Label Magnesium Sulphate Infusion in Severe Sepsis and Septic Shock

Conditions
-----------------
Severe Sepsis, Septic Shock

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe sepsis and septic shock Exclusion Criteria: pregnancy oral bleeding age < 18 years liver cirrhosis acute arrhythmias advanced malignancy or a mean arterial pressure (MAP) < 65 mmHg refractory to vasopressors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| severe sepsis and septic shock<br> | Drug: Magnesium Sulfate<br>* 2 gram in 1 hour<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microvascular flow index | Directly prior to and after 1 hour of magnesium sulphate (MgS) infusion (2 gram) systemic hemodynamic variables, sublingual SDF images and standard laboratory tests, were obtained. | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microcirculation, SDF, magnesium sulfate
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.

Official Title
-----------------
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: WF10


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Required: Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count <= 200 cells/mm3. Allowed: PCP prophylaxis with aerosolized pentamidine in patients with CD4 count > 200 cells/mm3, only at the discretion of the treating physician. Patients must have: HIV positivity. Absolute CD4 count of 150 - 500 cells/mm3. At least 6 months of prior zidovudine therapy. No active opportunistic infection requiring ongoing therapy. Life expectancy of at least 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Neoplasm other than basal cell carcinoma of the skin. Clinically significant cardiac disease. Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing. Unwilling to comply with protocol requirements. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: Antiretroviral agent or interferon. Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic agents, or other drugs that can cause neutropenia or significant nephrotoxicity. Rifampin or rifampin derivatives. Systemic anti-infectives. Required: At least 6 months of prior zidovudine. Active drug or alcohol abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: WF10|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antiviral Agents, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Erythropoietin decrease stress responses and inflammation in trauma patient.

Detailed Description
-----------------
Transfusion of blood products has many disadvantages. Erythropoietin is used to increase red blood cells production and decrease such disadvantages.In some studies anti inflammatory effects is shown for Erythropoietin. One of the most problems in the intensive care unit is stress response. we are going to evaluate effects of erythropoietin on oxidative stress and inflammation in trauma patient in intensive care unit.

Official Title
-----------------
Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit

Conditions
-----------------
Multiple Trauma

Intervention / Treatment
-----------------
* Drug: erythropoietin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All multiple trauma patients>16 years with informed consent Exclusion Criteria: Hypertension Allergy Erythroid leukemia Pregnancy and breast feeding Pre operative patient Severe cardiovascular and cerebrovascular diseases Thromboembolic disorders

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: erythropoietin<br>* 300mg/kg erythropoietin 3 times on the first week of admission<br>* Other names: EPREX;|
| Placebo Comparator: 2<br> | Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| apachi 2 saps 30 days mortality |  | untill discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30 days mortality |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple trauma
Case Control Psychological Autopsy of Suicide

Study Overview
=================
Brief Summary
-----------------
Suicide is a leading cause of death worldwide, and identifying risk factors has been considered as the key initiative of suicide prevention. Considering that, the study aimed to explore the factors leading towards suicide in Pakistan through Case-Control Psychological Autopsy of Suicide. Also, the study aimed to Translate, Adapt and Validate American Association of Suicidology (AAS) Semi-Structured Interview for Psychological Autopsy (Generic Version, 2018).

Official Title
-----------------
Psychological Autopsy: An Investigation to Explore Antecedents, Sequelae and Causes of Case Control Suicide Equivocal Behavior

Conditions
-----------------
Suicide, Fatal Suicide, Non Fatal Suicidal Behavior

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The age of the deceased by suicide and living controls will range from 10 to 35 years. The key informants will be of 18 years of age and above without any learning disability. The key informants will be a close family member or immediate friend. Only suicides took place in 2019 to September 2021. Exclusion Criteria: If contact was deemed to pose a risk to the safety of the researcher (likely intoxication; history of or potential for violence). Informants who are not willing to give written informed consent will be excluded from the study. Informants who are taking any psychological help in the past and present will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Case (Fatal Suicide) | |
| Control<br>Control (Non-Fatal Suicidal Behavior) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Semi-structured Interview for Psychological Autopsy | American Association of Suicidology Semi-Structured Interview for Psychological Autopsy | Upto 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cases, Controls